|
|||||||||
|
|
|
|
|
|
|
|
|
|
|
HEMATOPOIESIS
From the Department of Cell Differentiation, Institute
of Molecular Embryology and Genetics, Kumamoto University, Japan;
Center for Tsukuba Advanced Research Alliance and Institute of Basic
Medical Sciences, University of Tsukuba, Japan; and Department of
Molecular Biology and Molecular Oncology, Genentech, South San
Francisco, CA.
A critical role for the endothelium of yolk sac and dorsal aorta
has been shown in embryonic hematopoiesis. A stromal cell line derived
from yolk sac, YSCL-72, has been chosen to search for a novel molecule
associated with embryonic hematopoiesis. Analysis between YSCL-72 and
an adult aorta-derived endothelial cell line, EOMA, demonstrated that
activated leukocyte cell adhesion molecule (ALCAM, or CD166) was
specifically expressed in YSCL-72 but not in EOMA. Immunohistochemical
study showed that ALCAM was expressed in the endothelium of yolk sac
and dorsal aorta but not in adult aorta. ALCAM-transfected EOMA cells
supported development of hematopoietic progenitor cells compared with
vector-transfected EOMA cells, suggesting that ALCAM
appeared to be crucial for hematopoiesis. In addition, ALCAM was found
to be involved in capillary tube formation and hemangioblast
differentiation. Taken together with these findings, ALCAM is
highly associated not only with embryonic hematopoiesis but also vasculoangiogenesis.
(Blood. 2001;98:2134-2142) The interaction between the stromal and
hematopoietic cells plays an important role in proliferation and
differentiation of hematopoietic stem cells and progenitors. Several
groups have investigated the potential functions of stromal cells
derived from various hematopoietic sites. However, because of the
complexity of these cell-to-cell interactions, the molecular mechanisms
by which stromal and hematopoietic cells interact with each other remain obscure. In contrast to the complicated morphology of bone marrow hematopoietic regions, the type of stromal cells surrounding hematopoietic cells in the yolk sac and dorsal aorta is purely endothelial. Thus, analyses of the interactions between embryonic stromal endothelial cells and hematopoietic stem/progenitor cells can
shed light on new molecules that are associated with hematopoiesis during embryonic development.
Accumulating evidence suggests that the endothelium of both the dorsal
aorta in the AGM (aorta-gonad-mesonephros) region and the yolk sac is
involved in hematopoiesis, particularly in the development of
hematopoietic stem cells. It has been reported that small clusters of
CD34+ hematopoietic cells attached to the endothelium of
dorsal aorta and the yolk sac in human and mouse embryos, consistent
with the importance of endothelial cells in the support of
hematopoietic stem cell or progenitor cell development.1-4
In addition, air/liquid organ cultures of AGM regions demonstrated
expansion of hematopoietic stem cells,5 indicating that
this region, which contained endothelial and hematopoietic cell types,
was involved with the amplification and/or maintenance of pluripotent
hematopoietic cells. From these findings, we hypothesized that
hematopoietic stem cells are expanded on endothelial cells and novel
factors produced from endothelial cells would support expansion of
these stem cells.
Yolk sac blood islands also contain endothelial cells surrounding
hematopoietic cells. However, the existence of yolk sac-derived hematopoietic stem cells able to repopulate adult irradiated mice is
still controversial. Yoder and colleagues6 showed that
hematopoietic stem cells derived from the yolk sac could repopulate
recipient mice when these cells were first injected into fetal livers
in newborns, suggesting that hematopoietic stem cells in yolk sac are
somehow different from those in AGM, fetal liver, or bone marrow. One
possible explanation of these experiments was that embryonic
hematopoietic stem cells found in yolk sac need a suitable microenvironment (ie, the fetal liver stroma) to adjust to the adult
hematopoietic environment. These findings also suggest that the
endothelium in yolk sac might have an important role in hematopoietic stem cell development, and Fennie et al clearly demonstrated that CD34+ yolk sac-derived endothelial cell lines, YSCL-72 and
YSCL-71, extensively supported hematopoiesis in vitro.7 In
addition, we have shown that YSCL-72 has modest ability to maintain
hematopoietic stem cells.4 These results led us to attempt
to find a novel factor in yolk sac endothelium involved in the
maintenance of hematopoietic stem or progenitor cells.
Activated leukocyte cell adhesion molecule (ALCAM, or CD166), also
known as KG-CAM, neurolin, and BEN/DM-GRASP/SC1, is a cell surface immunoglobulin superfamily member that is involved with homophilic adhesion as well as binding to CD6.8-14 BEN was
reported to be a marker in the developing chick central and peripheral nervous system and was also expressed on hematopoietic progenitor cells.15 Recently, the human homolog of ALCAM,
hematopoietic cell antigen (HCA), was isolated by Uchida et
al,16 and this protein was detected on the most primitive
subset of hematopoietic stem cells as well as on myeloid progenitors in
bone marrow. Because of its known adhesive activity, HCA was speculated
to play a role in the homophilic binding of hematopoietic progenitor
cells, perhaps to the stromal cell.17 Here we support this
conjecture by demonstrating that mouse ALCAM18 was found
to be expressed in yolk sac-derived endothelial cell line, YSCL-72,
which was known to support the development of hematopoietic stem cells
and progenitors. To examine a functional role of ALCAM in hematopoiesis
and vasculoangiogenesis in vitro, ALCAM+ hematopoietic
cells and endothelial cells derived from AGM or yolk sac were
investigated. These results suggested the involvement of ALCAM not only
in maintenance of hematopoietic stem cells or expansion of progenitor
cells but also in endothelial tube formation. Accordingly, these
findings imply that ALCAM might be a key adhesion molecule involved
with the development of hematopoietic stem cells and endothelial progenitors.
Production of monoclonal antibodies
Cloning of ALCAM
Cells lines E11 yolk sac-derived endothelial cell lines, YSCL-72 and YSCL-71, were maintained in HAVA medium as described elsewhere.4 Mouse EOMA was maintained in Dulbecco modified Eagle medium/10% fetal bovine serum (JRH Bioscience, Lenexa, KS), and ALCAM-transfected EOMA cell lines (GM2, GM10, and vector alone) were adjusted to HAVA medium containing 600 µg/mL G418 (Gibco, Grand Island, NY). OP9 stromal cell line is maintained in a modified minimum essential media ( -MEM) (Gibco) supplemented with 20% fetal
bovine serum.
Mice and antibodies Timed pregnant mice (C57BL/6) or 2- to 3-month-old male mice (C57BL/6) were purchased from Harlan Sprague Dawley Laboratory (Dallas, TX) or Japan SLC (Shizuoka, Japan). Congenic C57BL6, Ly5.2 male mice were purchased from the National Cancer Institute (Frederick, MD). Mice were killed by cervical dislocation.The antibodies used for fetal liver stem cell sorting were all obtained
from Pharmingen (San Diego, CA). Biotinylated antibodies for lineage
cocktail contain anti-CD4 (GK1.5), anti-CD8 (53-6.7), anti-B220 (6B2),
anti-Gr-1 (8C5), and antierythroid (TER119). Other antibodies include
phycoerythrin (PE)-conjugated anti-Sca-1 antibody (E13) and
fluorescein (FITC)-conjugated anti-c-Kit antibody (2B8). Secondary
reagent includes allophycoerythrin-labeled streptavidin (Caltag
Laboratories) and FITC-labeled donkey antirabbit IgG (Jackson ImmunoResearch, West Grove, PA). The antibodies used for isolation of
hematopoietic progenitor cells from AGM or yolk sac were
rabbit-anti-CD34 polyclonal antibody, PE-conjugated anti-c-Kit
antibody, and biotinylated anti-ALCAM antibody. The antibodies used for
isolation of endothelial precursor cells from AGM or yolk sac were
PE-conjugated anti-Flk-1 antibody (Avas12 Isolation of fetal liver hematopoietic stem cells and long-term reconstitution assay Mouse fetal liver stem cells were isolated from E13.5 as described previously.4 Purified liver stem cells (Lin Sca-1+c-Kit+) were cultured
with irradiated stromal cells for 7 or 25 days. Cultured cells were
trypsinized, and one third of culture (corresponding to 1000 stem
cells) or one sixth of culture (corresponding to 500 stem cells) was
transplanted into the recipients as described elsewhere.4
All mice used as donors for long-term reconstitution were Ly5.1, and
C57Bl/6-Ly5.2 recipient mice were lethally irradiated with 10.50 Gy
(1050 rad) as a single dose from 137Cs source. Freshly
isolated stem cells or progenitor cells cultured on stromal cells were
injected into the tail vein along with 1 × 106 whole
bone marrow cells from Ly5.2 congenic source for
radioprotection. Groups of 6 or 8 mice were injected for each
cell type. For analysis of reconstitution, mice were bled from the
retro-orbital sinus and assayed for the presence of Ly5.1+
cells 12 weeks after transplantation as previously
described.4
Isolation of hematopoietic progenitors from AGM and yolk sac and differentiation of hematopoietic cells on stromal cells E10.5 AGM and yolk sacs were dissected out, and single cells were obtained as previously reported.19 Cells were fractionated for CD34+c-Kit+ cells, and they were further divided on the basis of the expression of ALCAM by FACS. Sorted cells were cultured with irradiated stromal cells (GM2 or vector alone) for 7 days. Cells were trypsinized, and adherent cells including stromal cells were eliminated after passing through a G10 column (Amersham Pharmacia Biotech, Uppsala, Sweden). Numbers of nonadherent cells were scored, and the frequency of c-Kit+ cells was analyzed by FACS. Harvested 1000 nonadherent cells were subsequently cultured for 7 days with methylcellulose medium (Methocult M3234, StemCell Technologies, Vancouver, BC) containing 100 ng/mL stem cell factor (SCF) (R & D Systems, Minneapolis, MN), 100 ng/mL interleukin-3 (IL-3) (R & D Systems), 100 ng/mL IL-6 (a gift from Dr T. Sudo, Toray Industries, Kamakura, Japan), and 2 U/mL erythropoietin (Epo) (a gift from Snow-Brand Milk Products). The number of colonies containing more than 50 cells was scored on day 7, and morphologies of colonies (G, granulocyte colonies; GM, granulocyte-macrophage; M, macrophage; E, erythroid burst; GEM, granulocyte-erythroid-macrophage; and GEMM, granulocyte-erythroid-macrophage-megakaryocyte) were evaluated under the microscope.Isolation of endothelial progenitors from AGM and yolk sac and differentiation of endothelial progenitors on OP9 cells E10.5 AGM- and yolk sac-derived cells were obtained as described above. A total of 500 Flk-1+PECAM-1+ALCAM+ or Flk-1+PECAM-1+ ALCAM cells from
yolk sac or AGM were plated on OP9 cells and cultured with 10 ng/mL
vascular endothelial growth factor (VEGF) (PeproTech, London, United
Kingdom) for 10 days. Cultured cells were fixed with 4%
paraformaldehyde and stained with anti-PECAM-1 antibody. For the
differentiation of
Flk-1+PECAM-1+ALCAM+ or
Flk-1+PECAM-1+ ALCAM
cells to hematopoietic cell lineage, 500 progenitors were cultured with
OP9 cells in the presence of 100 ng/mL SCF, 100 ng/mL IL-6, 2 U/mL Epo,
and 20 U/mL IL-7 (a gift from Dr T. Sudo) for 12 days. Nonadherent
cells were obtained after passing through a G10 column, the number of
cells was scored, and the frequency of c-Kit+ cells was
examined by FACS. For morphologic examination, cytospins were stained
with May-Grünwald-Giemsa solution.
Construct and production of human IgG fusion protein Soluble forms of ALCAM-Fc and CD4-Fc were constructed by fusion of the extracellular domain of ALCAM or CD4 and the Fc part of human IgG. ALCAM-Fc- or CD4-Fc-inserted expression vector was transfected to COS7 cells and cultured in serum-free medium as previously reported.20 Conditioned medium were harvested and purified over protein A column (Affi-Gel, Bio-Rad, Hercules, CA). After dialysis, purity was examined by Coomassie brilliant blue staining of sodium dodecyl sulfate gels and enzyme-linked immnunosorbent assay.Immunostaining of embryonic and adult endothelium E9.5 or E10.5 embryos were dissected out, and samples were fixed with 4% paraformaldehyde for 4 to 6 hours at 4°C. The embryos or aorta were then embedded in polyester wax and sectioned at 5 to 7 µm. Dewaxed with ethanol, sections were treated with 0.3% hydrogen peroxide in methanol and stained with anti-ALCAM antibody (1-2 µg/mL), anti-PECAM-1 antibody, or isotype-matched rat IgG overnight at 4°C as reported previously.19 Staining for cardiac muscle or smooth muscle, antisarcomeric actin antibody (-Sr-1) (Dako, Glostrup, Denmark), and antismooth muscle actin antibody (1A4)
(Dako) were incubated with horseradish peroxidase-conjugated Envision
polymer reagent (K1391) (Dako) at room temperature for 45 minutes and
sections were incubated with these antibody-binding reagents for 30 minutes. Color reaction was performed using diaminobenzidine as
described elsewhere.19
Binding assay Mononuclear cells from mouse bone marrow were fractionated for ALCAM+ or ALCAM cells, and
1 × 104 cells of each fraction were plated onto
vector-transfected cells or GM2. After 4 or 5 hours of incubation at
37°C, cells were washed 3 times with phosphate-buffered saline and
the remaining cells were harvested. Cells were then stained with
PE-conjugated anti-CD45 antibody (Pharmingen), and the frequency of
CD45+ cells was analyzed by FACS.
Analysis of endothelial tube formation in Matrigel Analysis of capillary formation in Matrigel (Becton Dickinson) was performed as per the manufacturer's instructions; 200 µL Matrigel (No. 354234) was applied into a 4-well plate (Nalge Nunc, Rochester, NY) and incubated at 37°C for 30 minutes. YSCL-71 cells were trypsinized, and 5 × 104 cells were suspended with 400 µL Dulbecco modified Eagle medium/10% fetal bovine serum and plated onto Matrigel. Then 25 µg ALCAM-Fc or CD4-Fc was added to Matrigel culture, and it was incubated for 60 hours. Tube formation in Matrigel was observed under a microscope, and the number of capillary tubes in a random field from each of 4 wells was quantitated.Statistical analysis Statistical evaluations of data were conducted by using the Student t test for per-comparison analysis. The data are presented as means ± SD.
ALCAM-transfected endothelial cell line (GM2) supports hematopoiesis We hypothesized that ALCAM might be involved in expansion of hematopoietic stem or progenitor cells. To examine the potential role of ALCAM in hematopoiesis, a cDNA encoding this protein was transfected into the EOMA endothelial cell line derived from adult mouse aorta, and the ability of the resultant cells to support hematopoiesis was investigated. As seen in Figure 1A, ALCAM was highly expressed in both the yolk sac-derived endothelial cell line, YSCL-72, as well as in the established ALCAM-transfected cell lines, while ALCAM expression was not detected in vector-transfected EOMA cells. To analyze whether homophilic interactions via ALCAM between hematopoietic cells and stromal cells occur, ALCAM+ mononuclear cells from mouse bone marrow were incubated with vector-transfected stromal cells and ALCAM-transfected stromal cells (GM2) (Figure 1B). ALCAM+ hematopoietic cells adhered to GM2 in higher frequency than ALCAM stromal cells
(22.9% ± 1.3% vs 17.8% ± 2.6%, P < 0.05). It
was reported previously that YSCL-72 has the ability both to expand yolk sac-derived CD34+ hematopoietic
progenitors7 and maintain hematopoietic stem cells.4 Fetal liver-derived hematopoietic stem cells
(LinSca-1+c-Kit+) were cocultured
with either YSCL-72 or ALCAM-transfected cells (GM2), and expanded
hematopoietic cells were analyzed (Figure 1C). This figure illustrates
that the number of nonadherent cells were significantly greater in
coculture with GM2 compared with coculture with vector-transfected
cell. Similar data were obtained with the GM10, which is also an
ALCAM-transfected EOMA cell line (data not shown). Morphologic analysis
of cells stained with May-Grünwald-Giemsa revealed that blastlike
cells were observed in ALCAM-transfected cocultures, whereas most cells
expanded on vector-transfected cells were mature hematopoietic cells
(data not shown). These data are consistent with the hypothesis that
ALCAM-mediated adhesion is involved with the expansion of hematopoietic
progenitor cells by endotheliallike stromal cell lines.
To examine whether ALCAM was involved in maintenance of hematopoietic
stem cells, fetal liver-derived hematopoietic stem cells (Lin
Immunostaining of embryonic and adult endothelium with anti-ALCAM antibody While the data described above are consistent with a role for ALCAM in the regulation of hematopoiesis, it was important to demonstrate the expression of this protein in the appropriate hematopoietic sites in vivo. Figure 2 illustrates that endothelial cells in both dorsal aorta and vitelline artery were weakly positive for ALCAM in the E9.5 embryo, whereas endothelial cells surrounding yolk sac hematopoietic cells and mesenchymal cells differentiated from mesoderm were strongly positive for this protein. In E10.5 embryos, the expression of ALCAM was clearly observed in dorsal aorta endothelium (Figure 2Bi,ii) and, as with the staining observed in the E9.5 yolk sac, both endothelial cells and closely attached mesenchymal cells were strongly positive for ALCAM in the yolk sac (Figure 2Biii). These immunostaining data were consistent with the observation of highly expressed ALCAM in yolk sac-derived endothelial cell line, YSCL-72, by FACS (Figure 1A).
BEN/DM-GRASP/SC1, which is the avian homolog of ALCAM, is a marker in the developing nervous system,8-10 and E9.5- or E10.5-derived notochord and floor plate were intensely stained with anti-ALCAM antibody16 (Figure 2Ai,ii). In E10.5 embryo, the epithelium in trachea and esophagus was also positive for ALCAM (Figure 2Bii), and in heart, myocardium was reactive for anti-ALCAM antibody, although the endocardium was not labeled with anti-ALCAM antibody (Figure 2Bii). This latter observation indicates that the differential expression of ALCAM in endothelium of different organs existed at an early embryonic stage. Finally, expression of ALCAM in adult aorta and endocardium was examined (Figure 2C). In accordance with the absence of ALCAM expression in the adult aorta-derived cell, EOMA, neither endothelium of aorta nor endocardium in adult mice was positively stained with anti-ALCAM antibody (Figure 2Civ). These immunohistochemical data, together with previous studies,16 demonstrate that both the endothelium of hematopoietic sites as well hematopoietic progenitor cells express this homophilic adhesion molecule. Hematopoietic cells derived from yolk sac and AGM were expanded on ALCAM-transfected endothelial cell Because ALCAM appears to mediate a homophilic adhesion, we hypothesized that homophilic binding between hematopoietic cells and stromal cells might play an important role in expansion of hematopoietic cells in yolk sac. Because ALCAM appears to be expressed in yolk sac endothelium (Figure 2), we first investigated the expression of ALCAM on hematopoietic cells derived from the yolk sac. E10.5 yolk sac cells were sorted for CD34+c-Kit+ cells and further subdivided at the expression of ALCAM (Figure 3A). Approximately 11.2% of CD34+c-Kit+ cells derived from E10.5 yolk sac were ALCAM+ cells. CD34+c-Kit+ALCAM+ cells or CD34+c-Kit+ALCAM cells were
cocultured with ALCAM-transfected cells (GM2) or vector-transfected cells to examine the role of ALCAM (Figure 3B). GM2 expanded more nonadherent cells from
CD34+c-Kit+ALCAM+ cells than vector
alone (Figure 3Ba, black column), and the frequency of
c-Kit+ cells within those nonadherent cells was higher in
GM2 than vector-transfected cells (Figure 3Bb, black column). Although
CD34+c-Kit+ALCAM cells cultured
on GM2 generated the most nonadherent cells (Figure 3Ba, white column),
the frequency of c-Kit+ cells (Figure 3Bb, white column)
was lower than that from ALCAM+ cells in GM2 (Figure 3Bb,
gray column). These data were consistent with the suggestion that ALCAM
might be involved in interaction between hematopoietic cells and
stromal cells and that homophilic interaction between them would
mediate yolk sac-derived hematopoietic cells in immature
state.
As shown in immunohistochemical staining in Figure 2B, endothelium in
dorsal aorta was strongly positive for ALCAM, and it is therefore
hypothesized that ALCAM also acts in hematopoiesis in E10.5 dorsal
aorta. To examine a role of ALCAM on hematopoiesis in E10.5 AGM, the
expression of ALCAM in AGM-derived hematopoietic progenitors was
analyzed. Hematopoietic cells from the E10.5 AGM region were sorted for
CD34+c-Kit+ cells, and this double-positive
population was subdivided on the expression of ALCAM (Figure
4A). Approximately 36.5% of the hematopoietic cells within the CD34+c-Kit+
population were ALCAM+. As was found for yolk sac-derived
hematopoietic progenitor cells (Figure 3B), GM2 supported more
c-Kit+ nonadherent cells derived from AGM than
vector-transfected cells (Figure 4Ba, black column; Figure 4Bb, gray
column). The morphology of hematopoietic cells expanded on
vector-transfected cells appears to be macrophagelike cells (Figure
4Ca); on the contrary, blastlike hematopoietic cells were expanded on
GM2 (Figure 4Cb). Those expanded hematopoietic cells on
vector-transfected cells and GM2 were subsequently cultured in
methylcellulose medium containing SCF, IL-3, IL-6, and Epo for 7 days.
No colonies were detected from cells expanded on
vector-transfected cells; on the other hand, 24 ± 6 colonies (G/GM
colony, 11 ± 4; M colony, 9 ± 2; E colony, 1 ± 1; GEM/GEMM colony, 2 ± 0) developed from cells expanded on GM2.
CD34+c-Kit+ALCAM To examine the involvement of ALCAM in the expansion of hematopoietic cells in vitro, a soluble from of ALCAM was constructed as a chimera with the Fc region of human immunoglobulin (ALCAM-Fc). ALCAM-Fc was subsequently added to the coculture of ALCAM+ hematopoietic cells and GM2 cell, and the effects of soluble ALCAM on the expansion of c-Kit+ cells was investigated (Figure 4D). Addition of ALCAM-Fc in the coculture mediated the complete inhibition of expanded nonadherent cells (Figure 4Da), and ALCAM-Fc partially inhibited the frequency of c-Kit+ cells (Figure 4Db), suggesting that ALCAM may play an important role in hematopoiesis at the AGM region via a homophilic adhesive interaction between the endothelium and hematopoietic progenitor cells. The role of ALCAM in development of endothelial precursor cells Because ALCAM was highly expressed at endothelium in dorsal aorta and yolk sac in E10.5 embryo (Figure 2B), we examined how ALCAM was involved in development of endothelial precursor cells in vitro. First, the frequency of ALCAM+ endothelial precursor cells was analyzed by FACS (Figure 5A). E10.5 AGM- or yolk sac-derived endothelial precursor cells were sorted for Flk-1+CD31+ cells and further subdivided on the basis of the expression of ALCAM. In agreement with the immunohistochemical experiments above (Figure 2), most of Flk-1+CD31+ endothelial progenitor cells were ALCAM+ in E10.5-derived AGM and yolk sac. To characterize the potential involvement of ALCAM in endothelial precursor cell development, ALCAM+ or ALCAM cells were
further fractionated from Flk-1+CD31+
endothelial precursor cells and cultured in vitro on the OP9 cell in
the presence of VEGF. After 9- or 10-day cocultivation, cultured cells
were fixed and stained with anti-CD31 antibody to examine the
differentiation of endothelial precursor cells. Two types of
differentiated endothelial clusters, a tightly packed sheetlike cluster
or slenderly elongated cordlike cluster, were observed (Figure 5B). It
appeared that ALCAM+ precursor cells formed larger
sheetlike and cordlike endothelial clusters than those from
ALCAM endothelial precursor cells. Macroscopic
observation clearly demonstrated that largely extended
CD31+ endothelial clusters were detected in AGM-derived
endothelial precursor cells, particularly in ALCAM+
endothelial precursor cells compared with endothelial clusters derived
from yolk sac (Figure 5C). Quantitative analyses were done in both
sheetlike and cordlike clusters (Figure 5D). The number of sheetlike
clusters observed in AGM-derived endothelial precursor cells was higher
than those from yolk sac, and ALCAM+ endothelial precursor
cells differentiated to more sheetlike clusters than those from
ALCAM endothelial precursor cells in AGM and yolk sac
(Figure 5D, left). As similarly observed for sheetlike clusters, more
cordlike clusters were detected in ALCAM+ endothelial
precursor cells than in ALCAM endothelial precursor
cells. However, the difference between the number of cordlike clusters
between ALCAM+ and ALCAM endothelial
precursor cells in AGM or yolk sac was not significant (Figure 5D,
right). These data strongly suggested that ALCAM+
endothelial precursor cells have high potential to develop into more
mature vascular structures on OP9 cells.
To examine how ALCAM was associated with the formation of endothelial
clusters, ALCAM-Fc was added to the culture, and the number of 2 types
of endothelial clusters derived from AGM was analyzed (Figure 5E).
Interestingly, ALCAM-Fc inhibited the formation of cordlike clusters
but not the formation of sheetlike clusters. These data clearly
demonstrated that ALCAM was involved in the formation of elongated
vessellike endothelial clusters. We next investigated whether ALCAM
would affect tube formation by endothelial cells suspended in Matrigel.
The ALCAM+ yolk sac-derived endothelial cell line,
YSCL-71, was used for this assay. YSCL-71 cells were plated onto
Matrigel in the presence of ALCAM-Fc or control CD4-Fc, and tube
formation was analyzed after 60 hours. ALCAM-Fc mediated the inhibition
of tube formation (Figure 6Aiii) compared
with the control CD4-Fc (Figure 6Aii). Scoring the extent of tube
formation in each well clearly demonstrated that ALCAM-Fc suppressed
the endothelial tube formation in Matrigel, suggesting that ALCAM might
be also involved in angiogenesis in vivo. These data, together with the
results shown in Figure 5, are consistent with a role for
ALCAM-mediated adhesion in endothelial cell development, particularly
in the formation of vessellike structures.
Analysis of differentiation of hematopoietic cells from ALCAM+ endothelial precursor cells Hemangioblast cells are the common precursor cells for hematopoietic and endothelial cells. However, cell surface markers to purify hemangioblast cells have not been reported yet. Because it has been demonstrated that differentiated embryonic stem cells expressing Flk-1 differentiate into both hematopoietic cells and endothelial cells in vitro,21 it has been speculated that hemangioblast cells might express Flk-1 in yolk sac or AGM. Because ALCAM is expressed on both embryonic hematopoietic as well as endothelial cells, we hypothesized that this protein might be a marker for hemangioblasts. Flk-1+CD31+ cells were analyzed to determine whether hematopoietic cells were differentiated from those endothelial precursor cells when coculture was done with OP9 cells in the presence of several kinds of cytokines (SCF, Epo, IL-6, IL-7) instead of VEGF (Figure 7). This experiment showed that although more hematopoietic cells were expanded from AGM-derived ALCAM cells and yolk sac cells, the highest frequency of
c-Kit+ cells was observed in hematopoietic cells derived
from ALCAM+ Flk-1+CD31+ cells
(Figure 7A,B). May-Grünwald-Giemsa staining revealed that immature hematopoietic cells were differentiated from
ALCAM+ Flk-1+CD31+ cells (Figure
7Cii). In contrast, maturated hematopoietic cells were differentiated
from ALCAMFlk-1+CD31+ cells in
AGM- or yolk sac-derived Flk-1+CD31+ cells
(Figure 7Ci,iii,iv).
These findings clearly demonstrated that
Flk-1+CD31+ cells derived from E10.5 AGM or
yolk sac have the ability to differentiate into hematopoietic cell
lineage in the presence of various cytokines on OP9 cells; in addition,
differentiated hematopoietic cells from
Flk-1+CD31+ALCAM+ cells in AGM were
less mature than ALCAM
The proliferation and differentiation of hematopoietic stem cells is dependent on a close association with stromal cells, which generate a diversity of regulatory factors, including cytokines and growth factors, and maintain adhesive interactions essential to the survival and function of the hematopoietic cells. It appears that adhesive interactions are likely to be responsible for the retention of hematopoietic cells in the microenvironment. In addition, adhesive interactions themselves may serve as growth or survival signals, and adhesion itself may modulate cytokine- or growth factor-dependent signals.22 Accordingly, these cell-to-cell and cell-to-extracellular matrix interactions are responsible not only for the localization of hematopoietic cells but also play an important role in the regulation of hematopoiesis in the hematopoietic microenvironment. Thus, it is of great interest to analyze how an adhesion molecule such as ALCAM is involved in hematopoiesis in the early stage of embryos. It has been reported that adhesion molecule ALCAM acts not only as a homophilic adhesion protein but also in heterophilic binding to CD6 in hematopoiesis, the immune response, and the nervous system.14,15,18,23 According to binding assays, the 3-membrane proximal constant immunoglobulinlike domains of human ALCAM have been shown to be involved in homophilic binding.14,24 In addition, it was demonstrated that the chicken homolog, BEN/ DM-GRASP/SC1, is required for formation of chicken myeloid colonies via homophilic binding.15 On the other hand, heterophilic interactions via CD6 were initially reported by Bowen et al to mediate hematopoietic cell binding to thymic epithelial cells.13 In this paper, to investigate a functional role of ALCAM in
hematopoietic cell and endothelial cell development in vitro, we
produced a soluble form of ALCAM to interfere with the function of this
protein in coculture experiments. Uchida et al16
hypothesized that HCA-HCA (human ALCAM) interactions would be involved
in cobblestone formation, and its homophilic binding might be important
for hematopoietic stem cells to remain undifferentiated. Although they
have demonstrated that more cobblestones were observed in
HCA+ progenitors than with HCA In contrast, our hypothesis is that ALCAM is involved in binding between stromal cell and hematopoietic cells, and ALCAM may support not only hematopoietic development but also maintain stem cells or progenitors undifferentiating. Indeed, we observed here an effect of ALCAM-Fc on primitive ALCAM+ hematopoietic cells development on ALCAM+ stromal cells (Figure 4). Because the inhibitory effect of ALCAM-Fc on expansion of c-Kit+ hematopoietic progenitors was not complete, we speculate that the amount of ALCAM-Fc used in this experiment may not be sufficient or that other adhesion molecules may be involved in the development of progenitors. Cortes et al17 also reported that HCA was expressed in primary bone marrow-derived stromal cells. Because they demonstrated that CD6 was expressed in a human stem cell population, they speculated that not only HCA but also CD6-expressing hematopoietic stem cell or progenitor might be expanded via homophilic and/or heterophilic binding.17 Although we clearly demonstrated that ALCAM acts to expand hematopoietic progenitor cells by the coculture of ALCAM+ hematopoietic cells and stromal cell in the presence of ALCAM-Fc, we cannot rule out the possibility that CD6 or other molecules are involved in hematopoiesis via heterophilic interaction with ALCAM. Vasculogenesis is the process by which hemangioblasts or angioblasts
proliferate and differentiate and form a primary vascular plexus. To
examine the ability of endothelial progenitors to develop in vitro, we
used endothelial progenitors and an OP9 coculture system as reported
previously25 and observed 2 types of endothelial clusters,
sheetlike or cordlike clusters, which developed from Flk-1+CD31+ endothelial progenitors in the AGM
and yolk sac. Interestingly, higher numbers of both types of
endothelial clusters were developed from ALCAM+ endothelial
progenitors, indicating that ALCAM+ endothelial progenitors
have the potential to develop extensively on OP9 cells compared with
ALCAM As far as effects on formation of endothelial clusters, addition of ALCAM-Fc resulted in impaired formation of cordlike structure, whereas suppression of sheetlike structures was not observed in the presence of ALCAM-Fc. It was previously demonstrated that Flk-1+ cells from embryonic stem cells differentiated to sheetlike endothelial clusters on OP9 cells.25 However, it is still unknown whether 2 types of clusters observed in our experiment were derived from same stage of endothelial progenitors, even though Flk-1+CD31+ cells were sorted for the coculture with OP9 cells. Angiogenesis is the process by which new capillaries are formed from preexisting vessels by processes including protease induction, migration, proliferation, differentiation, and morphogenesis of the cells into tubelike structures.26 We examined a role of ALCAM on the tube formation using a yolk sac-derived endothelial cell line, which is known to express ALCAM. Addition of ALCAM-Fc in the Matrigel assay mediated the inhibition of formation of tubelike structures, strongly suggesting that ALCAM plays a role in the tube formation, although the mechanism underlying this observation is still unknown. Although we expect that homophilic binding via ALCAM-ALCAM interactions might be involved in the development of hematopoietic cells, endothelial clusters, and tube-formation in Matrigel, we still cannot rule out the possibility of a contribution of heterophilic interaction via CD6-ALCAM. To understand how homophilic binding (ALCAM-ALCAM) or heterophilic binding (ALCAM-CD6) is involved in development of hematopoietic stem cells and endothelial progenitors, expression of CD6 on hematopoietic or endothelial progenitors in early-stage embryos should be investigated, and addition of blocking CD6 antibody to coculture with OP9 cell might be required. It will also be important to analyze the effects of in vivo loss of expression of ALCAM on hematopoietic and endothelial cell development in early-stage embryos. Finally, analysis of the effect of ALCAM on hematopoietic stem cell and endothelial progenitor development may provide an opportunity to dissect the hemangioblast development process during embryogenesis.
J.L., D.D., and L.A.L. are employed by Genentech, whose potential product was studied in the present work.
Submitted November 28, 2000; accepted June 8, 2001.
The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 U.S.C. section 1734.
Reprints: O. Ohneda, Center for TARA and Instutute of Basic Medical Sciences, University of Tsukuba, Tsukuba, 305-8577, Japan; e-mail: oohneda{at}tara.tsukuba.ac.jp; or T. Suda, Department of Cell Differentiation, IMEG, Kumamoto University, 2-2-1, Honjo, Kumamoto, 860-0811, Japan; e-mail: sudato{at}gpo.kumamoto-u.ac.jp.
1.
Young P, Baumheoter S, Lasky LA.
The sialomucin CD34 is expressed in hematopoietic cells and blood vessels during murine development.
Blood.
1995;85:96-105
2.
Tavian M, Coulombel L, Luton D, et al.
Aorta associated CD34(+) hematopoietic cells in the early human embryo.
Blood.
1996;87:67-72
3.
Wood H, May G, Healy L, et al.
CD34 expression patterns during early mouse development are related to modes of blood vessel formation and reveal additional sites of hematopoiesis.
Blood.
1997;90:2300-2311
4.
Ohneda O, Fennie C, Zheng Z, et al.
Hematopoietic stem cell maintenance and differentiation are supported by embryonic aorta-gonad-mesonephros region-derived endothelium.
Blood.
1998;92:908-919 5. Medvinsky A, Dzierzak E. Definitive hematopoiesis is autonomously initiated in the AGM region. Cell. 1996;86:897-906[CrossRef][Medline] [Order article via Infotrieve].
6.
Yoder M, Hiatt K, Mukherjee P.
In vivo repopulating hematopoietic stem cells are present in the murine yolk sac at day 9.0 postcoitus.
Proc Natl Acad Sci U S A.
1997;94:6776-6781
7.
Fennie C, Cheng J, Dowbenko D, et al.
CD34+ endothelial cell lines derived from murine yolk sac induce the proliferation and differentiation of CD34+ hematopoietic progenitors.
Blood.
1995;86:4454-4467
8.
Pourquie O, Coltey M, Thomas JL, et al.
A widely distributed antigen developmentally regulated in the nervous system.
Development.
1990;109:743-752 9. Tanaka H, Matsui T, Agata A, et al. Molecular cloning and expression of a novel adhesion molecule, SC1. Neuron. 1991;7:535-545[CrossRef][Medline] [Order article via Infotrieve]. 10. Burns FR, von Kannen S, Guy L, et al. DM-GRASP, a novel immunoglobulin superfamily axonal surface protein that supports neurite extension. Neuron. 1991;7:209-220[CrossRef][Medline] [Order article via Infotrieve]. 11. Peduzzi JD, Irwin MH, Geisert EE Jr. Distribution and characteristics of a 90 kDa protein, KG-CAM, in the rat CNS. Brain Res. 1994;640:296-307[CrossRef][Medline] [Order article via Infotrieve]. 12. Laessing U, Giordano S, Stecher B, et al. Molecular characterization of fish neurolin: a growth-associated cell surface protein and member of the immunoglobulin superfamily in the fish retinotectal system with similarities to chick protein DM-GRASP/SC-1/BEN. Differentiation. 1994;56:21-29[Medline] [Order article via Infotrieve].
13.
Bowen MA, Patel DD, Li X, et al.
Cloning, mapping, and characterization of activated leukocyte-cell adhesion molecule (ALCAM), a CD6 ligand.
J Exp Med.
1995;181:2213-2220
14.
Bowen MA, Bajorath J, Siadak AW, et al.
The amino-terminal immunoglobulin-like domain of activated leukocyte cell adhesion molecule binds specifically to the membrane-proximal scavenger receptor cysteine-rich domain of CD6 with a 1:1 stoichiometry.
J Biol Chem.
1996;271:17390-17396
15.
Corbel C, Pourquie O, Cormier F, et al.
BEN/SC1/DM-GRASP, a homophilic adhesion molecule, is required for in vitro myeloid colony formation by avian hemopoietic progenitors.
Proc Natl Acad Sci U S A.
1996;93:2844-2849
16.
Uchida N, Yang Z, Combs J, et al.
The characterization, molecular cloning, and expression of a novel hematopoietic cell antigen from CD34+ human bone marrow cells.
Blood.
1997;89:2706-2716
17.
Cortes F, Deschaseaux F, Uchida N, et al.
HCA, an immunoglobulin-like adhesion molecule present on the earliest human hematopoietic precursor cells, is also expressed by stromal cells in blood-forming tissues.
Blood.
1999;93:826-837 18. Bowen MA, Bajorath J, D'Egidio M, et al. Characterization of mouse ALCAM (CD166): the CD6-binding domain is conserved in different homologs and mediates cross-species binding. Eur J Immunol. 1997;27:1469-1478[Medline] [Order article via Infotrieve]. 19. Ohneda O, Ohneda K, Nomiyama H, et al. WECHE: a novel hematopoietic regulatory factor. Immunity. 2000;12:141-150[CrossRef][Medline] [Order article via Infotrieve].
20.
Yano M, Iwama A, Nishio H, et al.
Expression and function of murine receptor tyrosine kinases, TIE and TEK, in hematopoietic stem cells.
Blood.
1997;89:4317-4326 21. Nishikawa S-I, Nishikawa S, Hirashima M, et al. Progressive lineage analysis by cell sorting and culture identifies FLK1+VE-cadherin+ cells at a diverging point of endothelial and hemopoietic lineages. Development. 1998;125:1747-1757[Abstract].
22.
Verfaillie CM.
Adhesion receptors as regulators of the hematopoietic process.
Blood.
1999;92:2609-2612 23. Pollerberg GE, Mack TG. Cell adhesion molecule SC1/DMGRASP is expressed on growing axons of retina ganglion cells and is involved in mediating their extension on axons. Dev Biol. 1994;165:670-687[CrossRef][Medline] [Order article via Infotrieve]. 24. Skonier JE, Bowen MA, Emswiler J, et al. Mutational analysis of the CD6 binding site in activated leukocyte cell adhesion molecule. Biochemistry. 1996;35:14743-14748[CrossRef][Medline] [Order article via Infotrieve].
25.
Hirashima M, Kataoka H, Nishikawa S, et al.
Maturation of embryonic stem cells into endothelial cells in an in vitro model of vasculogenesis.
Blood.
1999;93:1253-1263 26. Gerwins P, Skoldenberg E, Claesson-Welsh L. Function of fibroblast growth factors and vascular endothelial growth factors and their receptors in angiogenesis. Crit Rev Oncol Hematol. 2000;34:185-194[Medline] [Order article via Infotrieve].
© 2001 by The American Society of Hematology.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
|
 |
|
  T. Yamashita, O. Ohneda, A. Sakiyama, F. Iwata, K. Ohneda, and Y. Fujii-Kuriyama The microenvironment for erythropoiesis is regulated by HIF-2{alpha} through VCAM-1 in endothelial cells Blood, August 15, 2008; 112(4): 1482 - 1492. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Yamashita, K. Ohneda, M. Nagano, C. Miyoshi, N. Kaneko, Y. Miwa, M. Yamamoto, O. Ohneda, and Y. Fujii-Kuriyama Hypoxia-inducible Transcription Factor-2{alpha} in Endothelial Cells Regulates Tumor Neovascularization through Activation of Ephrin A1 J. Biol. Chem., July 4, 2008; 283(27): 18926 - 18936. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S.-C. Choi, K. D. Kim, J.-T. Kim, J. W. Kim, H. G. Lee, J.-M. Kim, Y.-S. Jang, D.-Y. Yoon, K. I. Kim, Y. Yang, et al. Expression of human NDRG2 by myeloid dendritic cells inhibits down-regulation of activated leukocyte cell adhesion molecule (ALCAM) and contributes to maintenance of T cell stimulatory activity J. Leukoc. Biol., January 1, 2008; 83(1): 89 - 98. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Nagano, T. Yamashita, H. Hamada, K. Ohneda, K.-i. Kimura, T. Nakagawa, M. Shibuya, H. Yoshikawa, and O. Ohneda Identification of functional endothelial progenitor cells suitable for the treatment of ischemic tissue using human umbilical cord blood Blood, July 1, 2007; 110(1): 151 - 160. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Ibanez, M.-R. Sarrias, M. Farnos, I. Gimferrer, C. Serra-Pages, J. Vives, and F. Lozano Mitogen-Activated Protein Kinase Pathway Activation by the CD6 Lymphocyte Surface Receptor J. Immunol., July 15, 2006; 177(2): 1152 - 1159. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Hernandez-Gonzalez, I. Gonzalez-Robayna, M. Shimada, C. M. Wayne, S. A. Ochsner, L. White, and J. S. Richards Gene Expression Profiles of Cumulus Cell Oocyte Complexes during Ovulation Reveal Cumulus Cells Express Neuronal and Immune-Related Genes: Does this Expand Their Role in the Ovulation Process? Mol. Endocrinol., June 1, 2006; 20(6): 1300 - 1321. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Ikeda and T. Quertermous Molecular Isolation and Characterization of a Soluble Isoform of Activated Leukocyte Cell Adhesion Molecule That Modulates Endothelial Cell Function J. Biol. Chem., December 31, 2004; 279(53): 55315 - 55323. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. K. Saifullah, D. A. Fox, S. Sarkar, S. M. A. Abidi, J. Endres, J. Piktel, T. M. Haqqi, and N. G. Singer Expression and Characterization of a Novel CD6 Ligand in Cells Derived from Joint and Epithelial Tissues J. Immunol., November 15, 2004; 173(10): 6125 - 6133. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W Weichert, T Knosel, J Bellach, M Dietel, and G Kristiansen ALCAM/CD166 is overexpressed in colorectal carcinoma and correlates with shortened patient survival J. Clin. Pathol., November 1, 2004; 57(11): 1160 - 1164. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Gimferrer, M. Calvo, M. Mittelbrunn, M. Farnos, M. R. Sarrias, C. Enrich, J. Vives, F. Sanchez-Madrid, and F. Lozano Relevance of CD6-Mediated Interactions in T Cell Activation and Proliferation J. Immunol., August 15, 2004; 173(4): 2262 - 2270. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. W. Zimmerman, J. M. D. T. Nelissen, S. E. van Emst-de Vries, P. H. G. M. Willems, F. de Lange, J. G. Collard, F. N. van Leeuwen, and C. G. Figdor Cytoskeletal restraints regulate homotypic ALCAM-mediated adhesion through PKC{alpha} independently of Rho-like GTPases J. Cell Sci., June 1, 2004; 117(13): 2841 - 2852. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Fujiwara, K. Tatsumi, K. Kosaka, Y. Sato, T. Higuchi, S. Yoshioka, M. Maeda, M. Ueda, and S. Fujii Human Blastocysts and Endometrial Epithelial Cells Express Activated Leukocyte Cell Adhesion Molecule (ALCAM/CD166) J. Clin. Endocrinol. Metab., July 1, 2003; 88(7): 3437 - 3443. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Arai, O. Ohneda, T. Miyamoto, X. Q. Zhang, and T. Suda Mesenchymal Stem Cells in Perichondrium Express Activated Leukocyte Cell Adhesion Molecule and Participate in Bone Marrow Formation J. Exp. Med., June 17, 2002; 195(12): 1549 - 1563. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
 |
 |
|||||||
 |
 |
 |
 |
 |
 |
 |
 |
||
| Copyright © 2001 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||
Top
Abstract
Introduction
